6 completed. 6 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 6 |
| Phase 2 | 1 | Completed 1 |
Follow MDS: new trials by email Literature Review of MDS trials Research Report on MDS
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS) APR-246 + azacitidine, Azacitidine - MDS | Phase 3 | Completed | Aprea Therapeutics | 154 | 2019-01-11 | 2025-03-18 |
| Haploidentical Donor vs mMUD in Hematological Malignancies Peripheral blood stem cells - AML, ALL | Phase 2 / Phase 3 | Completed | DKMS gemeinnützige GmbH | 98 | 2018-01-01 | 2024-08-07 |
| Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML Decitabine, HYDROXYUREA - MDS | Phase 3 | Completed | Groupe Francophone des Myelodysplasies | 170 | 2014-10-14 | 2021-11-19 |
| Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Darbepoetin alfa, Placebo - MDS | Phase 3 | Completed | Amgen | 147 | 2011-12-21 | 2017-12-19 |
| Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts ON 01910.Na - Myelodysplastic Syndromes, MDS | Phase 3 | Completed | Traws Pharma, Inc. | 299 | 2010-11-01 | 2020-06-30 |
| Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129) Azacitidine - Leukemia, AML | Phase 3 | Completed | M.D. Anderson Cancer Center | 187 | 2009-04-21 | 2020-01-14 |
Myelodysplastic Syndromes (3) · Anemia, Refractory, with Excess of Blasts (1) · Leukemia (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myelomonocytic, Chronic (1)
Bone Marrow Diseases (3) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Leukemia, Myeloid (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Anemia (1) · Anemia, Refractory (1) · Chronic Disease (1) · Disease Attributes (1) · Leukemia (1) · Myelodysplastic-Myeloproliferative Diseases (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Azacitidine (2) · Darbepoetin alfa (1) · Decitabine (1) · Hydroxyurea (1) · ON 01910 (1) · eprenetapopt (1)
Amgen (1) · Aprea Therapeutics (1) · DKMS gemeinnützige GmbH (1) · Groupe Francophone des Myelodysplasies (1) · M.D. Anderson Cancer Center (1) · Traws Pharma, Inc. (1)
France (4) · Germany (3) · United States (3) · Belgium (2) · Italy (2) · Spain (2) · Austria (1) · Czechia (1) · Greece (1) · Switzerland (1)
David Sallman, MD, PhD (1) · Johannes Schetelig, Prof Dr med (1) · Richard E. Champlin, MD, BS (1) · Steven M. Fruchtman, MD (1)
PMID 26968357, PMID 27400247, PMID 33170934, PMID 33513373, PMID 36455187
2009 (1), 2015 (1)